<DOC>
	<DOCNO>NCT01195792</DOCNO>
	<brief_summary>The purpose study determine whether GSK1521498 cause weight loss obese otherwise healthy subject over-eating behaviour .</brief_summary>
	<brief_title>A 35 Day Study Investigate Effects GSK1521498 Bodyweight Obese Subjects With Over-Eating Behaviours .</brief_title>
	<detailed_description>This study test new drug may use treat over-eating behaviour pattern overweight obese people find difficult control . The drug work inhibit effect messenger molecule call opioids . These opioids naturally produce within human body , involve control much eat , pleasure get eat . We believe GSK1521498 might effective treatment obesity well know drug work similar binding site brain reduce pleasure get eating , especially high fat high sugar food . We also believe effect GSK1521498 great obese individual great severity over-eating behaviour , measure example exist questionnaire scale binge-eating compulsive eat behaviour . We perform variety simple test use computer , questionnaires eat assessment examine effect behaviour . We also ask people complete questionnaire see effect mood .</detailed_description>
	<mesh_term>Hyperphagia</mesh_term>
	<criteria>Obese essentially healthy male female 18 60 year age inclusive . Body Mass Index great equal 30 kg/m2 . Binge Eating Scale ( BES ) score great equal 19 screen assessment . A female subject childbearing potential must use one contraception method list protocol prior start study least 14 day receive last dose study medication . Male subject must agree use one contraception method list protocol time first dose study medication least 5 day receive last dose study medication . Capable give write informed consent , include compliance requirement restriction list information sheet informed consent form . A good understanding English require due high number questionnaire assessment subject require undergo . Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; 2x Upper limit Normal ( ULN ) ; alkaline phosphatase bilirubin &lt; 1.5x ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Must right hand ( requirement ensure consistency functional magnetic resonance imaging ( fMRI ) signal brain ) Has history clinically significant medically diagnose eating disorder ( diagnose and/or treat ) assess Diagnostic Statistical Manual Mental Disorders ( DSMIV/V ) criterion use Mini International Neuropsychiatric Interview ( MINI ) . Selfadministered Beck Depression Inventory II scale total score great 13 suicide question score great zero screening . Current history ( last 6 month ) Axis 1 psychiatric disorder assess DSMIV/V criterion use MINI . Subject , investigator/designee 's judgement , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behaviour and/or evidence suicidal ideation questionnaire e.g . type 4 5 Columbia Suicide Severity Rating Scale ( CSSRS ) last 6 month . History substance abuse dependence 6 month prior screen , determine Investigator/designee MINI . History regular high level alcohol consumption . Positive prestudy drug/alcohol screen . Smoking history include regular use tobacco nicotinecontaining product within 3 month prior screen Use prohibit medication . use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day prior first dose study medication . Subjects currently show stable bodyweight , judge PI/designee ( e.g . &gt; 5 % change within last 3 month ) Pregnant lactate female Medical history , concurrent medical condition laboratory result make subject unsuitable study . This include T1 T2 diabetes mellitus ( Fasting Blood Glucose ( FBG ) &gt; 7 mmol/L ) , untreated dyslipidaemia ( fast lipid profile Low Density Lipoprotein ( LDL ) cholesterol &gt; 5 mmol/L ) , uncontrolled hypertension History bariatric surgery obesity . QTcB QTcF &gt; 450 msec . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Current chronic history neurological disorder . A positive test HIV Hepatitis C. Sleep apnoea Gastrointestinal disease include inflammatory bowel disease , chronic diarrhea , Crohn 's malabsorption syndrome within past year Participated clinical trial receive investigational product within 90 day . Any contraindication logistical complication anticipate relation Magnetic Resonance Imaging ( MRI ) scan endpoint assessment , include : presence cardiac pacemaker electronic device ferromagnetic metal foreign body , claustrophobia , inability lie still back , waist circumference 170 cm body weight exceed maximum capacity MRI scanner ( 180 kg ) . Special dietary requirement ( e.g . vegetarian , vegan , religious , foodintolerant diet ) . Unsuitable cannulation . Subjects plan start calorie control diet major exercise routine . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Opioid receptor</keyword>
	<keyword>Body weight</keyword>
	<keyword>Over-eating behaviour</keyword>
	<keyword>Obesity</keyword>
	<keyword>Fat mass</keyword>
</DOC>